• In HFrEF, early sacubitril/valsartan initiation may improve outcomes, hasten LV remodeling

    6 days ago - By Healio

    Compared with later initiation, starting sacubitril/valsartan within 3 months of a diagnosis of HF with reduced ejection fraction was tied to better clinical outcomes and earlier left ventricular reverse remodeling, researchers reported.
    Despite patients who initiated sacubitril/valsartan early having lower baseline LVEF, improvements in the form of LV reverse remodeling were observed in less than 6 months, according to data published in ESC Heart Failure.
    “One-year mortality reaches 20% and 5-year mortality reaches 53% to 67% after the diagnosis of HF. The prevalence
    Read more ...